Who is sponsoring NCT04102150?

NCT04102150 is sponsored by Daiichi Sankyo Co., Ltd..

What drugs are being tested in NCT04102150?

Interventions in NCT04102150: Valemetostat Tosylate.

What condition does NCT04102150 study?

NCT04102150 studies Adult T-cell Leukemia/Lymphoma.

Is NCT04102150 still recruiting?

NCT04102150 is currently completed. Last updated 10 February 2025.

Last reviewed 2025-02-10 · How we verify

NCT04102150

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Valemetostat Tosylate (DS-3201b) Phase 2 Study in Relapsed or Refractory Adult T-cell Leukemia/Lymphoma

Completed Phase 2 Last updated 10 February 2025

What this trial tests

Phase 2 trial testing Valemetostat Tosylate in Adult T-cell Leukemia/Lymphoma in 25 participants. Completed in 27 October 2024.

Timeline

21 November 2019

Primary endpoint
24 April 2021

27 October 2024

Quick facts

Lead sponsor	Daiichi Sankyo Co., Ltd.
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	25
Start date	21 November 2019
Primary completion	24 April 2021
Estimated completion	27 October 2024
Sites	24 locations across Japan

Drugs / interventions tested

Valemetostat Tosylate — full drug profile →

Conditions studied

Adult T-cell Leukemia/Lymphoma — all drugs for Adult T-cell Leukemia/Lymphoma →

Sponsor

Daiichi Sankyo Co., Ltd. — full company profile →

Who can join

20 and older, any sex, with Adult T-cell Leukemia/Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This Phase 2 study will be conducted to assess the efficacy and safety of valemetostat tosylate (DS-3201b) in participants with relapsed or refractory adult T-cell leukemia/lymphoma (r/r ATL).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

EZH2: a novel target for cancer treatment.
Duan R, Du W, Guo W. · · 2020 · cited 652× · PMID 32723346 · DOI 10.1186/s13045-020-00937-8
EZH2-Targeted Therapies in Cancer: Hype or a Reality.
Eich ML, Athar M, Ferguson JE, Varambally S. · · 2020 · cited 188× · PMID 32978169 · DOI 10.1158/0008-5472.can-20-2147
Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease.
Bhat KP, Ümit Kaniskan H, Jin J, Gozani O. · · 2021 · cited 181× · PMID 33469207 · DOI 10.1038/s41573-020-00108-x
An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma.
Izutsu K, Makita S, Nosaka K, Yoshimitsu M, et al · · 2023 · cited 118× · PMID 36150143 · DOI 10.1182/blood.2022016862
The roles of EZH2 in cancer and its inhibitors.
Liu Y, Yang Q. · · 2023 · cited 100× · PMID 37148376 · DOI 10.1007/s12032-023-02025-6
Mechanisms of action and resistance in histone methylation-targeted therapy.
Yamagishi M, Kuze Y, Kobayashi S, Nakashima M, et al · · 2024 · cited 95× · PMID 38383791 · DOI 10.1038/s41586-024-07103-x
Methylation across the central dogma in health and diseases: new therapeutic strategies.
Liu R, Zhao E, Yu H, Yuan C, et al · · 2023 · cited 79× · PMID 37620312 · DOI 10.1038/s41392-023-01528-y
New Insights Into the Role of Phenotypic Plasticity and EMT in Driving Cancer Progression.
Bhatia S, Wang P, Toh A, Thompson EW. · · 2020 · cited 63× · PMID 32391381 · DOI 10.3389/fmolb.2020.00071

Verify or expand the search:

Other trials of Valemetostat Tosylate

Trials testing the same drug.

NCT07303387 — Efficacy and Safety of the Valemetostat in Patients With Selected Solid Tumors. · Phase 2 · not yet recruiting
NCT06632977 — Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial · Phase 2 · recruiting
NCT04703192 — Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Periphe · Phase 2 · active not recruiting

Other recruiting trials for Adult T-cell Leukemia/Lymphoma

Currently open trials in the same condition.

NCT07388563 — Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma · Phase 1 · recruiting
NCT07356245 — Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma · Phase 2 · recruiting
NCT07159620 — Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients · Phase 2 · recruiting
NCT05978141 — A Registry for People With T-cell Lymphoma · recruiting

Other Daiichi Sankyo Co., Ltd. trials

Trials by the same sponsor.

NCT06074705 — A Study of DS-1471a In Subjects With Advanced Solid Tumors · Phase 1 · terminated
NCT05606094 — Real-World Observational Study to Describe Treatment Patterns in Patients With HER2-Positive Locally Advanced or Metasta · completed
NCT04914520 — Study of VN-0200 in Japanese Healthy Adults and Elderly Subjects · Phase 1 · completed
NCT04818398 — Study of Single-Ascending Doses of DS-6016a in Healthy Japanese Subjects · Phase 1 · completed
NCT04821674 — Study of DS-5670a (COVID-19 Vaccine) in Japanese Healthy Adults and Elderly Subjects · Phase 1, PHASE2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04102150 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Daiichi Sankyo Co., Ltd.
Last refreshed: 10 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04102150.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing